Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as XL147 (SAR245408)
XL147 · 6 trials · 9 indications
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | All subjects will receive single-agent XL147 dosed daily |
| Arm 1 | EXPERIMENTAL | XL147 (SAR245408) + letrozole |
| Arm 2 | EXPERIMENTAL | XL765 + letrozole |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | Continuous daily dosing |
| 3 | EXPERIMENTAL | Continuous daily dosing |
| Name | Type | Description |
|---|---|---|
| XL147 (SAR245408) | DRUG | dosed as capsules taken orally daily |
| XL765 (SAR245409) | DRUG | given orally twice daily as capsules |
| letrozole (Femara) | DRUG | given orally once daily as tablets |
| trastuzumab | BIOLOGICAL | administered by IV once every 3 weeks |
| paclitaxel | DRUG | administered by IV once every week |
| XL147 (SAR245408), | DRUG | Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing |
| carboplatin | DRUG | Intravenous injection dosed once every three weeks |
| Erlotinib | DRUG | Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing |
Inclusion Criteria: * The subject has a histologically confirmed diagnosis of EC (endometrioid, serous, clear cell adenocarcinoma, adenosquamous carcinoma, or mixed histology, any grade) that is advanced (ie, persistent, locally advanced) or recurrent, and is incurable by standard therapies and has...
Top 20 of 49 competitors
XL147 is an investigational small molecule studied in oncology for breast cancer, endometrial cancer, and other advanced solid tumors. Clinical trials have evaluated it both as a single agent and in combinations, including with letrozole in breast cancer, with trastuzumab or paclitaxel plus trastuzumab in metastatic breast cancer, and with paclitaxel and carboplatin in solid tumors.
XL147 is developed by Sanofi, which trades on the New York Stock Exchange under the ticker SNY. The compound originated at Exelixis and is also identified by the code SAR245408 in Sanofi's development nomenclature.
XL147 is in clinical development. Its trials span Phase 1 and Phase 2, and the program is listed at Phase 1 overall. All four recorded studies are completed, with no active trials currently listed, and the drug is investigational rather than approved.
Four completed trials are registered for XL147. NCT01082068 tested XL147 or XL765 with letrozole in breast cancer, NCT01042925 tested XL147 with trastuzumab or paclitaxel plus trastuzumab in metastatic breast cancer, NCT01013324 studied advanced or recurrent endometrial carcinoma, and NCT00756847 combined XL147 with paclitaxel and carboplatin in solid tumors.
Yes. XL147 and SAR245408 refer to the same investigational compound. XL147 was the original Exelixis designation, and SAR245408 is the Sanofi code used after Sanofi took over development, so search results and trial records under either name describe the same drug.
Across the four completed studies, 233 patients have been enrolled in XL147 clinical trials. Enrollment ranged from 42 participants in the metastatic breast cancer study to 72 in the breast cancer combination study with letrozole, and the trials were conducted in the United States, France, Spain, and Belgium.